There is currently a lack of available treatments that can prevent or modify the progression of neurodegenerative disorders like Alzheimer’s disease (AD) and Parkinson’s disease (PD), which affect millions of people in Europe. Despite robust research efforts to accelerate biomarker discovery, at this time there are few secure, accessible ways for clinical samples and data to be discovered and shared within the neurodegenerative disease research community.

EPND brings together 29 partners from the public and private sectors and is managed by two public partners, the University of Maastricht and the University of Leicester, and two private partners. The outcome of this program will be the establishment of EPND as a European infrastructure to facilitate access to clinical samples and data to accelerate biomarker discovery and support the development of neurodegenerative disease diagnostics and therapeutics that could touch lives all over the globe.

As one of the 29 partners in this project, Svar is proud to embark on this venture to establish a collaborative platform for efficient sample and data sharing, leveraging and linking existing European research infrastructures to accelerate the discovery of biomarkers, new diagnostics, and treatments for the benefit of people with neurodegenerative diseases such as Alzheimer’s and Parkinson’s.